Go to ...


Value Investing Research Since 2006

RSS Feed

Wednesday, May 23, 2018

Archives for June 2014

Vertex Pharmaceuticals Annual Valuation – 2014 $VRTX

Vertex Pharmaceuticals does not qualify for either the Defensive Investor or the Enterprising Investor. The Defensive Investor has major concerns with the lack of earnings stability over the last ten years, the lack of dividends, the insufficient earnings growth, and the high PEmg and PB ratios.

Older Posts››